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A B S T R A C TObjectives: To quantify the annual excess direct medical costs of vision
impairment from the perspective of the Bureau of National Health
Insurance in Taiwan and to examine whether the costs vary by severity
and duration of vision impairment. Methods: A retrospective matched
cohort analysis was conducted by using data from the Longitudinal
Health Insurance Databases between January 1, 2000, and December 31,
2008. All patients newly diagnosed with vision impairment were
categorized as having moderate vision loss, severe vision loss, or
blindness. Each patient with vision impairment was matched to one
randomly selected patient with normal vision by age (1 year) and sex.
At each level of vision impairment, generalized linear models were used
to quantify the total annual excess costs and component costs incurred
in the first and second years. Results: Vision impairment was asso-
ciated with significantly higher crude excess medical costs. At each
level of vision impairment, the total crude medical costs weresee front matter Copyright & 2013, International
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ondence to: Meng-Ting Wang, 9 F, No.161, Section 6attributable to different resource utilization and dominated by
non–eye-related medical care. After adjusting for covariates, the first-
year annual excess costs increased with escalating severity of vision
impairment: New Taiwan (NT) $9894 for moderate vision loss, NT
$22,760 for severe vision loss, and NT $52,687 for blindness. Similarly,
the second-year adjusted costs were estimated as NT $3477, NT $19,532,
and NT $28,272 for moderate vision loss, severe vision loss, and
blindness, respectively. Conclusions: Consistent with Western coun-
tries, vision impairment is associated with significantly increased
health care costs in Taiwan. The excess costs seem to increase with
severity of vision impairment and decrease in the second year.
Keywords: claims database analyses, direct medical costs, matched
cohort study, vision impairment.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Vision impairment is a serious health problem, currently affecting
more than 285 million people worldwide [1]. Vision impairment
not only causes damaged visual capability but also increases the
risk of injuries [2,3], hip fractures [4,5], falls [3,6], accidents [7,8],
depression [9,10], and mortality [11,12]. The economic burdens of
vision impairment on health care systems have been found to be
substantial in Asia [13] and Western countries [14–16].
The incremental annual medical costs of vision loss were also
estimated to be significant [15,17]. Javitt et al. [17] analyzed a 5%
random sample of all Medicare beneficiaries in the United States,
reporting that patients with blindness incurred the highest
annual costs, US $4680 more than did those with normal vision,
followed by those with severe and moderate vision loss. Similarly,
another US study observed escalating excess costs by increased
severity of visual impairment among individuals aged 40 years
and older [15]. The two studies, however, were either limited by
their inclusion of patients aged 69 years or older [17] or subject to
the use of self-reported data [15].
Few studies have evaluated whether annual excess medical
costs vary by time since the occurrence of blindness. The annualhealth care cost of blindness was estimated to increase by US
$7356 in the first year in comparison with nonblind patients,
while the excess costs decreased to US $1329 in the following
years [18]. Nevertheless, the reported subsequent annual medical
costs were confined to blindness and were estimated from
patients with diverse follow-up durations.
Furthermore, annual component expenditures for vision
impairment were observed to be different among studies in the
literature [15,19]. Total medical costs of vision impairment were
reported to be dominated by inpatient care in the Medicare
program [19], as opposed to be outweighed by home health care
from examining the Medical Expenditures Panel Survey data [15].
The discrepancy might be due to the analyses of only a special
segment of the overall population [19] or the inclusion of subjects
enrolled in different private or public health programs [15].
Accordingly, assessment of the medical costs from nationwide
claims data could overcome these drawbacks.
Roberts et al. [13] adopted a prevalence-based approach to
estimate the costs of visual impairment in Japan. However, the
direct health costs associated with visual impairment might
be overestimated because of the inclusion of conditions that
were not vision impairing. In addition, the costs were estimatedSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Furthermore, severity of vision impairment was not considered,
which might threaten the generalizability. As a result, the use of
a different approach to address the above-mentioned issues for
the estimation of the excess direct medical costs of vision
impairment is needed in Asia.
This study aimed to quantify the total and component direct
medical costs of vision impairment by analyzing the claims data
of the Taiwan universal National Health Insurance (NHI) pro-
gram, and to examine whether the medical costs vary by severity
or differ in the first and second years following occurrence of
vision impairment.Methods
Data Source
This study used a matched cohort study design by analyzing
data retrieved from Longitudinal Health Insurance Databases
(LHIDs) from January 2000 to December 2008. The Taiwan NHI
program is a comprehensive and universal health insurance
program in which up to 99% of the 23 million inhabitants of
Taiwan are enrolled [20]. The LHID contains all transactions of
de-identified and encrypted medical claims of 1,000,000 NHI
beneficiaries who were randomly selected from the entire NHI
beneficiaries enrolled in the year 2005. Distributions of gender,
age, and medical expenditures of the subjects retrieved in
LHIDs are similar to those of the entire enrollees [21]. Most
importantly, comprehensive medical resource utilizations of
each beneficiary from emergency and inpatient/outpatient ser-
vices are available in LHIDs. In addition, the NHI claims database
has been used extensively in evaluating the economic burden of
various diseases [22,23]. Performing analyses using LHIDs,
accordingly, provides a unique opportunity to estimate the
increased medical expenditures associated with vision impair-
ment. Access to and use of LHIDs for this study was approved
by the National Health Research Institutes, which manages the
databases.
Study Population Identification
All the patients newly diagnosed with vision impairment were
identified within the entire beneficiaries in LHIDs between
January 2001 and December 2006. These patients were referred
as cases and further classified according to the worst vision
impairment category attained during the 6-year period by using
the International Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) codes: blindness (ICD-9-CM codes
369.0–369.08), severe vision loss (ICD-9-CM codes 369.1–369.4),
and moderate vision loss (ICD-9-CM codes 369.6–369.9). The
above-mentioned ICD-9-CM codes have been used in classifying
different levels of vision impairment previously [17,19]. The date
of the worst diagnosis of vision impairment was defined as the
index date. Patients without continuous enrollment in the year
before the index date as well as 2 years following the index date
were excluded to ensure the availability of all medical resource
utilization information. Each case was matched to one randomly
selected control from all LHID beneficiaries with normal vision by
age (1 year) and sex. Control patients were assigned the same
index date as their corresponding case patients. Cases with
vision impairment and their matched controls were followed
for 2 years from the index date.
Estimation of Excess Direct Medical Costs
Costs of vision impairment were analyzed from the perspective
of the Bureau of National Health Insurance because of theimplemented universal health insurance with comprehensive
coverage of medical care in Taiwan. Specifically, the direct
medical costs of both cases and controls were examined during
the first and second years after the index date. These medical
costs included all direct medical costs reimbursed to the health
care provider, such as physician fees, diagnostic fees, procedure
fees, and prescribed medications. Components of the excess
direct medical costs were examined and categorized into inpa-
tient, outpatient, and emergency care. In addition, total excess
direct medical costs were categorized into eye-related and
non–eye-related costs on the basis of information regarding
physician specialty. Costs incurred in the different years were
adjusted for inflation using the medical care Consumer Price
Index and presented in 2010 New Taiwan (NT) dollars [24]. US $1
equated NT $30.16 on August 13, 2012.
Statistical Analyses
The baseline characteristics of the cases and controls, measured
during the year before the index date, were compared by using
Wilcoxon signed-rank tests for continuous variables and McNe-
mar’s tests for categorical variables, respectively.
The proportions of cases and controls with previous
ophthalmologic-related diseases including glaucoma, retinopa-
thy, cataract, retinal vascular occlusion, and macular degenera-
tion were examined in the year before the index date at each
level of vision impairment. The corresponding ICD-9-CM codes
are listed in Table 1 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.vhri.2013.01.00.
The crude and adjusted annual excess direct costs incurred in
the first and second years for the cases over matched controls
were quantified by using generalized linear models with a
gamma-distribution and log-link function. Neither an ordinary
least square regression model with log transformation nor the
two-part model was used to estimate the excess costs. Use of
Duan smearing estimators for modeling costs by ordinary least
square regressions is needed to retransform costs from a log
scale to the original scale; however, the estimated costs could be
biased [25]. Because of less than 5% of patients with zero medical
cost in this study, a logistic regression used in the first part of the
two-part model is not expected to obtain a stable estimate of
probability of patients with any direct medical cost. Use of a
generalized linear model to model the cost data has been viewed
as an efficient method because of direct interpretations of the
estimated costs and the ability to handle zeros in the costs data
[26]. Potential confounders included age, sex, geographical area
of health care facilities, any visit to medical centers, preindex
medical costs with log transformation, and comorbidities includ-
ing cardiovascular diseases, diabetes mellitus, central nervous
system disorders, dementia, and cancer.
Multivariate analyses were performed separately for each
category of vision impairment in which all the covariates were
adjusted for. Estimated 95% confidence intervals (CIs) for the
crude and adjusted excess medical costs were calculated by using
bootstrap methods with 2000 replications. All the analyses were
carried out by using SAS version 9.2 (SAS Institute, Cary, NC, USA)
and STATA 10.1 (STATA, College Station, TX, USA).Results
During the study period, a total of 2508 cases of vision impair-
ment were identified, of which 1993, 217, and 298 patients were
categorized as moderate vision loss, severe vision loss, and
blindness, respectively (Fig. 1). An equal number of matched
controls were randomly selected for each category of vision
impairment.
Table 1 – Characteristic comparisons between cases and matched controls.
Variables Blindness Severe vision loss Moderate vision loss
Cases
(n ¼ 298)
Controls
(n ¼ 298)
Cases
(n ¼ 217)
Controls
(n ¼ 217)
Cases
(n ¼ 1993)
Controls
(n ¼ 1993)
Age (y),
mean  SD
49.2  27.0 49.2  27.0 54.0  23.8 54.0  23.7 27.2  24.8 27.2  24.7
Males, n (%) 152 (51.0) 152 (51.0) 95 (43.8) 95 (43.8) 1036 (52.0) 1036 (52.0)
Comorbidities, n
(%)
Cardiovascular
diseases
64 (21.5) 49 (16.4) 49 (22.6) 34 (15.7) 132 (6.6) 94 (4.7)y
Diabetes mellitus 74 (24.8) 47 (15.8)y 33 (15.2) 29 (13.4) 107 (5.4) 98 (4.9)
Central nervous
system
disorder
43 (14.4) 10 (3.4)y 29 (13.4) 13 (6.0)y 90 (4.5) 43 (2.2)y
Dementia 16 (5.4) 3 (1.0)y 8 (3.7) 5 (2.3) 28 (1.4) 8 (0.4)y
Cancer 14 (4.7) 6 (2.0) 13 (6.0) 3 (1.4)y 31 (1.6) 18 (0.9)y
Geographical area of health care facilities, n (%)z
Northern 121 (40.6) 128 (43.0) 53 (24.4) 93 (42.9)y 591 (29.7) 862 (43.3)y
Central 75 (25.2) 74 (24.8) 62 (28.6) 49 (22.6) 1,142 (57.3) 462 (23.2)y
Southern 71 (23.8) 61 (20.5) 85 (39.2) 54 (24.9)y 160 (8.0) 497 (24.9)y
Eastern 31 (10.4) 35 (11.7) 17 (7.8) 21 (9.7) 100 (5.0) 172 (8.6)y
Any visit to
medical centers,
n (%)
132 (44.3) 84 (28.2)y 95 (43.8) 44 (20.3)y 589 (29.6) 384 (19.3)y
Preindex costs§
(NT$)
median (IQR)
23,971
(7854–67,916)
9463
(3023–28,288)y
16,227
(7332–48,646)
10,154
(3861–23,474)y
9864
(4384–20,751)
5724
(2408–12,910)y
IQR, interquartile range; NT, New Taiwan.
 Matching variables.
y P value less than 0.05 based on the analysis of Wilcoxon signed-rank test or McNemar’s test.
z The mode of geographical area of health care facility was selected if appropriate.
§ Exchange rate: US $1 ¼ NT $30.16 on August 13, 2012.
VA L U E I N H E A LT H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 5 7 – 6 3 59Table 1 compares the baseline characteristics of the cases and
their matched controls. Across each category of vision impair-
ment, the proportions of all examined comorbidities and any
visit to medical centers, as well as the median of preindex annual
medical costs, were higher in cases than in controls. Further-
more, the majority of eye-related diseases occurred more fre-
quently in cases than in controls (see Table 2 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.vhri.2013.01.00).
The crude first-year annual excess costs increased signifi-
cantly with severity of vision impairment (Table 2): NT $14,539
(95% CI 10,407–18,991) for moderate vision loss, NT $38,020 (95%
CI 24,028–53,852) for severe vision loss, and NT $86,219 (95%
CI 61,370–114,635) for blindness. A similar trend was present for
the second-year annual excess medical costs. In addition, there
was a substantial decrease in the second-year crude annual
excess costs as compared with the first-year excess costs for
moderate vision loss and blindness, but not for severe vision loss.
The inpatient and outpatient services together constituted
around 97% of the total excess costs across the three categories of
vision impairment (Fig. 2A). The first-year inpatient costs
accounted for more than 50% of the total annual excess costs
for blindness, but the percentage declined to 35% and 21% for
severe and moderate vision loss, respectively. However, outpati-
ent services dominated the first-year component costs for mod-
erate and severe vision loss (71% and 58%, respectively), but
decreased to 39% for blindness. Similar component costs were
observed in the second year. Fig. 2B shows that non–eye-related
excess costs were substantially higher than eye-related excess
costs across the three levels of vision impairment yearly. Notably,
the proportion of the total excess costs from non–eye-related
services increased as vision impairment progressed, ranging from
85% to 97% for the first year and 93% to 98% for the second year.
The adjusted annual excess medical costs of the cases over
controls are presented in Table 3. Despite a substantial reductionin the adjusted excess costs compared with the crude costs, cases
with each level of vision impairment still had significantly higher
adjusted excess costs. Specifically, the first-year annual adjusted
excess medical costs increased with escalating severity of vision
impairment, with blindness being observed to incur the highest
adjusted excess costs (NT $52,687; 95% CI 35,473–72,668), followed
by severe vision loss (NT $22,760; 95% CI 10,409–34,182) and
moderate vision loss (NT $9894; 95% CI 4409–15,932). Similarly,
the second-year annual adjusted excess costs increased with
increasing severity of vision impairment in spite of the decreased
magnitude of the excess costs as compared with the first-year
costs.Discussion
The current study found that patients with any degree of vision
impairment based on the ICD-9-CM codes had significantly higher
direct medical costs than those without impaired vision. The
crude annual excess direct costs were found to increase with
escalating severity of vision impairment. When examined as
component costs, over half of the total excess costs of blindness
were attributable to inpatient care, whereas the majority of the
total excess costs of severe or moderate vision loss were driven
by outpatient services. When segmented by eye-related and
non–eye-related costs, the crude annual excess costs were
dominated by non–eye-related medical care regardless of varying
levels of vision impairment. In addition, the adjusted excess
medical costs of vision impairment remained substantial and
increased with vision impairment severity across the 2-year
period, but decreased from the first year to the second year
regardless of vision impairment severity.
The adjusted excess costs of vision impairment from this
study were lower than those estimated in middle-aged adults
Fig. 1 – Study flow diagram.
Table 2 – Annual crude excess medical costs during a 2-year period by different levels of vision loss.
Vision impairment First year Second year
Crude excess
expenditures (NT$)
95% CI Crude excess
expenditures (NT$)
95% CI
Blindness 86,219 61,370–114,635 57,679 34,044–83,142
Severe vision loss 38,020 24,028–53,852 45,140 27,328–65,110
Moderate vision loss 14,539 10,407–18,991 10,326 6344–14,299
CI, confidence interval; NT, New Taiwan.
 Exchange rate: US $1 ¼ NT $30.16 on August 13, 2012.
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estimated the annual excess medical care expenditures as US
$1037 for visual impairment and US $2157 for blindness, and the
second study [17] reported the average excess annual medical
costs to be US $2538, US $3708, and US $4680 for moderate vision
loss, severe vision loss, and blindness, respectively. Even after
inflating the costs estimated from the two above-mentioned
studies to 2010 value, our estimated excess direct costs of vision
impairment seemed to be relatively low than those of the two
studies, which might be attributable to methodological differ-
ences in costing. First, the two above-mentioned studies [15,17]
did not estimate the costs of vision impairment on a yearly basis.
Second, the records of utilizations of nursing home care and
long-term care were not available from LHIDs. Third, differences
in the health care systems across countries might also contri-
bute to the lower estimated excess costs of vision impairmentin this study. This is consistent with in general the higher health
care costs observed in the Western world as compared with
those in Asia [27].
We observed that the excess costs of vision impairment
decreased from the first year to the second year, which was
in accord with the study by Frick et al. [18] analyzing the
PharMetrics database. In the beginning of incident vision impair-
ment, patients may have the greatest intensity of health care
utilization for eye-related conditions or complications from
vision loss, such as falls [3,6] or depression [9,10]. As time goes
by since vision being impaired, a better physical and psychiatric
adaptation might be developed, resulting in less subsequent
excess costs.
We also found that the annual excess component costs varied
greatly across severity of vision impairment. In line with one
previous study [19], the majority of our observed total excess
Fig. 2 – (A) Annual component costs of cases than controls during a 2-year period by severity of vision impairment. (B)
Comparison of excess direct medical costs by inpatient, outpatient, and emergency care during a 2-year period by severity of
vision impairment.
Table 3 – Annual adjusted excess medical costs during a 2-year period by different levels of vision loss.
Vision impairment First year Second year
Adjusted excess
expenditures (NT$)
95% CI Adjusted excess
expenditures (NT$)
95% CI
Blindness 52,687 35,473–72,668 28,272 10,638–43,643
Severe vision loss 22,760 10,409–34,182 19,532 8,461–29,393
Moderate vision loss 9894 4409–15,932 3477 423–6170
CI, confidence interval; NT, New Taiwan.
 Adjusted for age, sex, comorbidities, geographical area, any visit to medical center, and preindex costs. Exchange rate: US $1 ¼ NT $30.16 on
August 13, 2012.
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hospital expenditures in blindness were reported to be relatively
low in another study [15], probably because patients with a mixed
severity of vision impairment and blindness were included foranalyses. However, patients with severe or moderate vision loss
were observed to have a greater cost from outpatient services,
probably because their relatively stable vision required more
outpatient follow-up visits instead of hospitalizations.
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a significant role in the total excess costs of vision impairment,
which is similar to the report by Javitt et al. [17]. Studies have
linked vision impairment to increased risks of secondary events,
such as depression [9,10], injuries [2,3], falls [3,6], and fractures
[4,5], which might contribute to the observed substantial non–
eye-related costs. In addition, patients with blindness or severe
vision loss had a relatively low proportion of eye-related costs in
comparison with patients with moderate vision loss probably
because further ophthalmologic interventions could do little
help to restore sights due to the high degree of severity [17].
Our findings suggest that allocating direct medical costs of visual
impairment should consider not only eye-related health care
utilizations but also other medical consequences attributable to
visual impairment. It is also suggested to spend resources in low-
vision rehabilitation, visual aids, and other supportive services
for reducing or avoiding the secondary events due to visual
impairment.
This study had several strengths. First, excess direct costs of
vision impairment were measured thoroughly because of the
implemented universal health insurance with comprehensive
coverage in Taiwan [20]. Second, the status of vision impairment
was classified into three levels on the basis of empirical ICD-9-CM
codes. Third, the use of a 2-year longitudinal observation pre-
cluded diverse follow-up durations among study subjects,
improving the estimation of the second-year excess costs. Finally,
LHIDs consist of a nationally representative random sample of
the entire beneficiaries enrolled in the NHI program [21] and
enhance the generalizability of our findings.
Several limitations in this study need to be addressed. Costs
of vision impairment might be underestimated because of the
unavailability of information on long-term care services in
LHIDs. It was estimated, however, that less than 1% of visually
handicapped people resided in a nursing home or long-term
care facility in Taiwan [28]. In addition, the estimated costs of
vision impairment might not be generalizable beyond the
national health insurance system. Nonmedical costs due to
vision impairment were reported to be substantial [29], and the
costs including house modifications/adjustments could not be
considered in this study. Furthermore, the validity of the ICD-9-
CM codes for classifying vision impairment might pose another
potential limitation. Nevertheless, the accuracy of vision
impairment classification seemed to be supported on the basis
of internal findings and external comparisons. First, the
observed phenomenon that the excess costs rose as vision
severity progressed was consistent with previous studies
[15,17]. Second, patients with blindness or severely impaired
vision had more eye-related diseases than did those with
moderate vision loss (see Appendix in Supplemental Materials
found at http://dx.doi.org/10.1016/j.vhri.2013.01.00). Third, our
estimated incidence of blindness is similar to that in the report
by Tsai et al. [30] (2.48 vs. 3.07 per 100,000 population per year).
Therefore, though the ICD-9-CM codes were not clinically
validated in LHIDs, these findings would support the classifica
tion of vision severity in our study.
In conclusion, consistent with the Western world, vision
impairment is associated with significantly excess medical
costs in Taiwan. In addition, the total excess medical costs
and inpatient component costs increase as severity of vision
impairment progresses. This study also highlights the
decreased annual excess costs in the subsequent year and the
substantial non–eye-related costs of vision impairment regard-
less of vision severity levels. Our findings are of public health
importance, suggesting the potential need in implementing
effective preventive programs to combat the most common
causes of diseases that lead to vision impairment. Efforts
should also be made to diagnose and treat those affected atan early stage to minimize future downstream costs from vision
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